X4 Pharmaceuticals, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on September 8, 2026, announcing a positive outcome from a Type C Meeting with the U.S. Food and Drug Administration related to the company's global 4WARD Phase 3 clinical trial.

Key Highlights

  • FDA Meeting Outcome: X4 Pharmaceuticals disclosed a positive outcome from a Type C Meeting with the U.S. Food and Drug Administration.
  • Trial in Focus: The meeting was related to the company's global 4WARD Phase 3 clinical trial.
  • Announcement Date: The press release was issued on September 8, 2026.
  • Exhibit Filed: A copy of the press release is filed as Exhibit 99.1 and incorporated by reference into the report.
  • Signatory: The filing was signed by David Kirske, Chief Financial Officer and Treasurer.

X4 Pharmaceuticals Discloses Type C FDA Meeting Result for 4WARD Trial

According to the filing, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued a press release on September 8, 2026, reporting what the company described as a "positive outcome" of its Type C Meeting with the U.S. Food and Drug Administration. The meeting was specifically related to the company's global 4WARD Phase 3 clinical trial. The filing was made under Item 8.01 (Other Events) of Form 8-K.

The 8-K does not provide additional detail about the substance of the FDA meeting's outcome beyond characterizing it as positive. The full press release, dated September 8, 2026, is attached as Exhibit 99.1 and incorporated by reference into the current report. The filing was submitted by David Kirske, who serves as the company's Chief Financial Officer and Treasurer.

X4 Pharmaceuticals is incorporated in Delaware and maintains its principal executive offices at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134. The company's common stock, with a par value of $0.001 per share, is registered on The Nasdaq Stock Market LLC under the trading symbol XFOR. The company indicated it is not an emerging growth company as defined under applicable SEC rules.

What Was Disclosed

X4 Pharmaceuticals filed an 8-K on September 8, 2026, disclosing a positive outcome from a Type C Meeting with the FDA concerning the global 4WARD Phase 3 clinical trial. The associated press release is filed as Exhibit 99.1.